JP2019532634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532634A5 JP2019532634A5 JP2019515418A JP2019515418A JP2019532634A5 JP 2019532634 A5 JP2019532634 A5 JP 2019532634A5 JP 2019515418 A JP2019515418 A JP 2019515418A JP 2019515418 A JP2019515418 A JP 2019515418A JP 2019532634 A5 JP2019532634 A5 JP 2019532634A5
- Authority
- JP
- Japan
- Prior art keywords
- macrophage
- use according
- selectively activated
- selective
- liver injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002540 macrophage Anatomy 0.000 claims 19
- 230000004913 activation Effects 0.000 claims 6
- 206010067125 Liver injury Diseases 0.000 claims 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 4
- 230000003213 activating effect Effects 0.000 claims 4
- 231100000753 hepatic injury Toxicity 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 231100000439 acute liver injury Toxicity 0.000 claims 1
- -1 amyodalone Chemical compound 0.000 claims 1
- 229940098164 augmentin Drugs 0.000 claims 1
- 210000004979 bone marrow derived macrophage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615923.8A GB201615923D0 (en) | 2016-09-19 | 2016-09-19 | Macrophage-based therapy |
| GB1615923.8 | 2016-09-19 | ||
| GB1707183.8 | 2017-05-05 | ||
| GBGB1707183.8A GB201707183D0 (en) | 2017-05-05 | 2017-05-05 | Macrophage-based therapy |
| PCT/GB2017/052769 WO2018051136A1 (en) | 2016-09-19 | 2017-09-18 | Macrophage-based therapy for use in the treatment of liver injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532634A JP2019532634A (ja) | 2019-11-14 |
| JP2019532634A5 true JP2019532634A5 (enExample) | 2020-11-12 |
| JP7115755B2 JP7115755B2 (ja) | 2022-08-09 |
Family
ID=60083347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515418A Active JP7115755B2 (ja) | 2016-09-19 | 2017-09-18 | 肝損傷の処置における使用のためのマクロファージに基づく治療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11285174B2 (enExample) |
| EP (2) | EP3515460B1 (enExample) |
| JP (1) | JP7115755B2 (enExample) |
| CN (1) | CN109789163A (enExample) |
| AU (1) | AU2017328913B2 (enExample) |
| WO (1) | WO2018051136A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2896548T3 (es) | 2015-10-30 | 2022-02-24 | Biolamina Ab | Métodos de producción de hepatocitos |
| GB2572005A (en) | 2018-03-16 | 2019-09-18 | Univ Court Univ Of Edinburgh | Macrophage-based therapy |
| CN112955161B (zh) * | 2018-09-06 | 2024-12-17 | 泰克年研究发展基金会公司 | 通过活化细胞修复组织 |
| GB202007905D0 (en) * | 2020-05-27 | 2020-07-08 | Univ Edinburgh | Cryopressing macrophages |
| CN111933006B (zh) * | 2020-07-30 | 2022-06-03 | 四川大学华西医院 | 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统 |
| CN114622017A (zh) * | 2020-12-14 | 2022-06-14 | 中山大学孙逸仙纪念医院 | Isg15、isg15诱导的巨噬细胞及其分泌物在肿瘤治疗中的应用 |
| WO2023075623A1 (en) * | 2021-10-26 | 2023-05-04 | Ineb (Instituto Nacional De Engenharia Biomédica) | Macrophage phenoypes for use in the treatment of intravertebral discs |
| CN115212320B (zh) * | 2022-08-04 | 2025-07-15 | 温州医科大学慈溪生物医药研究院 | 一种双靶向脂质体及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977029A (zh) | 2014-04-11 | 2014-08-13 | 中国人民解放军第四军医大学 | 经典激活的巨噬细胞在治疗肝纤维化的应用 |
| US10724003B2 (en) * | 2015-01-16 | 2020-07-28 | Agency For Science, Technology And Research | Method of differentiating human pluripotent stem cells into primitive macrophages |
-
2017
- 2017-09-18 EP EP17783964.4A patent/EP3515460B1/en active Active
- 2017-09-18 CN CN201780056623.2A patent/CN109789163A/zh active Pending
- 2017-09-18 AU AU2017328913A patent/AU2017328913B2/en active Active
- 2017-09-18 WO PCT/GB2017/052769 patent/WO2018051136A1/en not_active Ceased
- 2017-09-18 JP JP2019515418A patent/JP7115755B2/ja active Active
- 2017-09-18 EP EP25198861.4A patent/EP4640237A2/en active Pending
- 2017-09-18 US US16/331,787 patent/US11285174B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532634A5 (enExample) | ||
| JP2014148535A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| JP2019522037A5 (enExample) | ||
| CY1116799T1 (el) | Προληψη της υπογλυκαιμιας σε ασθενεις με σακχαρωδη διαβητη τυπου 2 | |
| JP2013541583A5 (enExample) | ||
| JP2016532516A5 (enExample) | ||
| HRP20201069T1 (hr) | Primjena tasimelteona pod uvjetima natašte | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| AR050783A1 (es) | Agentes terapeuticos con sal de nsaid y paracetamol | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| WO2016040462A3 (en) | Formulations and methods for treatment of metabolic syndrome | |
| JP2017516842A5 (enExample) | ||
| JP2014525749A5 (enExample) | ||
| JP2017531042A5 (enExample) | ||
| JP2019518052A5 (enExample) | ||
| Denison et al. | Effects of Organised Follow-Up of Behaviour That May Increase Risk of Disease in Adults [Internet] | |
| MX387263B (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma. | |
| WO2012145234A3 (en) | Cyclopropyl derivatives and methods of use | |
| Barry et al. | 406; Pharmacokinetic modeling of linezolid dosing regimens for multidrug resistant tuberculosis | |
| RU2016106521A (ru) | Способ обезболивания в стоматологии | |
| Reilly | Ask the doctor. I'm in my late 70s and have been getting about four cortisone shots a year for the past several years for the arthritis in my left knee. They really help with the pain, but I've heard that long-term, there could be bad side effects. Should I be worried? | |
| Ramachandran | Leptin and IL-6 Family Cytokines Synergize to Stimulate Müller Glia Reprogramming and Retina Regeneration | |
| Yang | Methylphenidate/procaterol interaction |